Johnson & Johnson

Johnson & Johnson Opens Innovation Center in London

The company will pursue medical device, drug and packaging developments at the London facility.

Johnson & Johnson today announced the opening of the Johnson & Johnson Innovation centre in London, one of four regional hubs being established this year in the world's leading innovation hotspots.  A part of Johnson & Johnson Innovation, the goal of the London innovation centre is to accelerate the best early stage science in the world and advance the development of new healthcare solutions.   

Your rating: None Average: 5 (1 vote)

Johnson & Johnson CEO: Drugmakers Want Higher Government, Insurance Payments

J&J executive Alex Gorsky says that while pharma firms are pleased at reforms, more change is needed.

Pharmaceutical companies are pleased that health-care reform means more patients have insurance and will be encouraged to take their medicine to avoid costly hospitalizations.

But, as Johnson & Johnson chief executive officer Alex Gorsky said Tuesday, drugmakers want private insurers or government programs such as Medicare and Medicaid to pay them for those drugs at a prices closer to their choosing.

Your rating: None Average: 4.5 (2 votes)

Johnson & Johnson Seeks Zytiga Marketing Approval

The company is looking for approval of its prostate cancer treatment.

The Food and Drug Administration will conduct a six-month review of Zytiga as a treatment for cancer in patients who have not received chemotherapy. The review means the FDA should finish its review, which began in June, in mid-December.

Your rating: None Average: 4 (1 vote)

Johnson & Johnson Invests in Chinese Biotech Firm

The company’s Johnson & Johnson (China) Investment division has acquired Guangzhou Bioseal Biotechnology to bolster its hemostasis product portfolio.

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. The acquisition was completed after obtaining all necessary Chinese Government approvals. Financial terms of the transaction are not being disclosed.

No votes yet

Johnson & Johnson Subsidiary Loses Drug-labeling Suit

The state of Arkansas won the ruling in its suit alleging the antipsychotic Risperdal included insufficient risk information in inserts and labels.

LITTLE ROCK, Arkansas — A Johnson & Johnson subsidiary downplayed and hid risks associated with the antipsychotic drug Risperdal, a jury determined Tuesday in Arkansas' billion-dollar lawsuit against Janssen Pharmaceuticals Inc.

Attorney General Dustin McDaniel's office is seeking fines of at least $1.2 billion for the 250,000 Risperdal prescriptions a state health coverage program paid over more than three years. The penalty will be decided Wednesday.

Your rating: None Average: 4 (1 vote)
Syndicate content